Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Session 9: Anti-Infective AntibodiesWednesday 9th November 2011. Moderator: Eszter Nagy

Session 9: Anti-Infective AntibodiesWednesday 9th November 2011. Moderator: Eszter Nagy not provided. IFN activation and to explore their potential application as novel therapeutics for the treatment of disease. Toward this objective we have employed combinatorial libraries of synthetic antibody fragments expressed on the surface of phage particles to select specifically for antibodies with these attributes and will discuss our efforts in isolating and characterizing these novel tools. [09.30–09.50] ‘Targeting the interferon network with synthetic antibodies’ Shane Miersch, Ashlesha Deshpande, Srilalitha kuruganti, Kumar Putcha, Mark Walter and Sachdev Sidhu University of Toronto, Toronto, Ontario, Canada Since the discovery of interferons (IFNs) in the late 1950’s, investigation has revealed that these cytokines possesspleiotropicanti – viral, anti – tumourandimmunomodulatory activity. In light of this they have found therapeutic application in the treatment of a variety of viral, oncologic and autoimmune disorders. Alternately, dysregulation of IFNs is thought to contribute to disease in other milieus, potentially contributing to a loss of immune tolerance and the development of autoimmunity. Nevertheless, structural variations in ligand – receptor interactions that are responsible for the divergent activities that the 13+ Type I IFNs exert in binding to a single heterodimeric receptor have yet to be elucidated. Considering the uncharacterized facets of IFN biology and its potential http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

Session 9: Anti-Infective AntibodiesWednesday 9th November 2011. Moderator: Eszter Nagy

Human Antibodies , Volume 20 (3) – Jan 1, 2011

Loading next page...
 
/lp/ios-press/session-9-anti-infective-antibodieswednesday-9th-november-2011-iJ5MhLACNK

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2011 by IOS Press, Inc
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-2011-0253
Publisher site
See Article on Publisher Site

Abstract

not provided. IFN activation and to explore their potential application as novel therapeutics for the treatment of disease. Toward this objective we have employed combinatorial libraries of synthetic antibody fragments expressed on the surface of phage particles to select specifically for antibodies with these attributes and will discuss our efforts in isolating and characterizing these novel tools. [09.30–09.50] ‘Targeting the interferon network with synthetic antibodies’ Shane Miersch, Ashlesha Deshpande, Srilalitha kuruganti, Kumar Putcha, Mark Walter and Sachdev Sidhu University of Toronto, Toronto, Ontario, Canada Since the discovery of interferons (IFNs) in the late 1950’s, investigation has revealed that these cytokines possesspleiotropicanti – viral, anti – tumourandimmunomodulatory activity. In light of this they have found therapeutic application in the treatment of a variety of viral, oncologic and autoimmune disorders. Alternately, dysregulation of IFNs is thought to contribute to disease in other milieus, potentially contributing to a loss of immune tolerance and the development of autoimmunity. Nevertheless, structural variations in ligand – receptor interactions that are responsible for the divergent activities that the 13+ Type I IFNs exert in binding to a single heterodimeric receptor have yet to be elucidated. Considering the uncharacterized facets of IFN biology and its potential

Journal

Human AntibodiesIOS Press

Published: Jan 1, 2011

There are no references for this article.